Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database

Suzuki, Masahiko; Arai, Masaki; Hayashi, Ayako; Ogino, Mieko

doi:10.1016/j.ensci.2020.100257

Cited by 14 publications

(12 citation statements)

References 25 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In episodes in which levodopa was prescribed, in any of its forms (associated either with carbidopa or benserazide), a higher number of commission errors was evidenced (≈90% of medication errors detected). This could be explained by multiple factors: (i) On the one hand, levodopa is the most prescribed antiparkinsonian drug for the management of PD, [31][32][33] thus the odds of finding more errors in PD patients treated with this drug are higher. (ii) On the other hand, it is the most suitable antiparkinsonian drug to individualize according to a patient's clinical needs, due to the numerous liberation (immediate or extended) and dosage forms available.…”

Section: Discussionmentioning

confidence: 99%

Antiparkinsonian Medication Reconciliation as a Strategy to Improve Safety by Preventing Medication Errors

Viudez‐Martínez

Ramírez‐López

López‐Nieto

et al. 2023

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background About 70% of neurologists report that PD patients do not get their medication properly when hospitalized, and 33% are prescribed contraindicated drugs. Objectives To execute medication reconciliation (MedRec) focused on antiparkinsonian drugs to identify, characterize and, eventually, prevent medication errors, thus promoting therapeutic quality and safety in daily practice. Methods An interventional, single‐center, 1 year, prospective study. All the patients who were hospitalized and had, at least, one active prescription containing an antiparkinsonian drug at hospital admission were included. MedRec was performed by following a three‐phased check: inpatient electronic prescription validation after assessing the outpatient medication schedule, review of the latest clinical report emitted by the Neurology Department/General Practitioner, and pharmacist‐driven interview of the patient and/or caregiver to confirm the information regarding medication gathered. Results A total of 171 admission episodes from 132 patients were registered (February 1, 2021, and January 31, 2022). Of 224 prescription lines involving antiparkinsonian drugs, 179 contained, at least, one medication error (59.8%). Commission errors (91.62%) were more frequent than omitted drugs (8.38%). The most common medication errors were related to timing (41.90%), frequency (21.23%), and dosing (19.55%). The implementation of this program prevented the erroneous administration of 2716 antiparkinsonian doses, 60% of the total number of doses prescribed. Interestingly, a significant relationship between the number of medication errors and having levodopa prescribed was evidenced (P < 0.05). A contraindicated drug was prescribed in almost one‐third of the episodes (29.82%). Conclusions Clinical pharmacists' implementation of an antiparkinsonians reconciliation program sharply reduced medication errors and prescription of contraindicated drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiparkinsonian Medication Reconciliation as a Strategy to Improve Safety by Preventing Medication Errors

Viudez‐Martínez

Ramírez‐López

López‐Nieto

et al. 2023

Movement Disord Clin Pract

View full text Add to dashboard Cite

show abstract

“…]90% of medication errors detected). This could be explained by multiple factors: i) On the one hand, levodopa is the most prescribed antiparkinsonian drug for the management of PD [30][31][32], thus the odds of finding more errors in PD patients treated with this drug are higher. ii) On the other hand, it is the most suitable antiparkinsonian drug to individualize according to a patient's clinical needs, due to the numerous liberation (immediate or extended) and dosage forms available.…”

Section: Discussionmentioning

confidence: 99%

Antiparkinsonian medication reconciliation: how preventing medication errors promotes therapeutic quality and safety

Viudez‐Martínez

Ramírez‐López

López‐Nieto

et al. 2022

Preprint

View full text Add to dashboard Cite

Aim: to design and implement a medication reconciliation protocol led by clinical pharmacists that allowed to identify, characterize and, eventually, prevent antiparkinsonian medication errors to promote therapeutic quality and safety in daily practice. Methods: This was an interventional, single-center, one-year, prospective study analyzing the impact of developing an antiparkinsonian medication reconciliation program. All the patients who were hospitalized and had, at least, one active prescription containing an antiparkinsonian drug at hospital admission were included. The medication reconciliation was performed by following a three-phased check: inpatient electronic prescription validation after assessing the outpatient medication schedule, review of the latest clinical report emitted by the Neurology Department, and pharmacist-driven interview of the patient and/or caregiver to confirm the information regarding medication gathered. Results: 171 admission episodes from 132 patients were registered between February 1, 2021, and January 31, 2022. Of 224 prescription lines involving antiparkinsonian drugs, 179 contained, at least, one medication error (59.8%). Commission errors (91.62%) were more frequent than omitted drugs (8.38%). The most common medication errors were related to timing (41.90%), frequency (21.23%), and dosing (19.55%). The implementation of the medication reconciliation program prevented the erroneous administration of 2716 antiparkinsonian doses, 60% of the total number of doses prescribed during this period. Interestingly, a significant relationship between the number of medication errors and having levodopa prescribed was evidenced (p<0.05). A contraindicated drug was prescribed in almost one-third of the episodes (29.82%). Conclusion: Clinical pharmacists’ implementation of an antiparkinsonian medication reconciliation program sharply reduced medication errors, and contraindicated drugs prescription.

show abstract

“…Recent Japanese research reported that levodopa is most commonly prescribed, followed by non-ergot dopamine agonists (DAs), both as monotherapy and in combination with levodopa. [6][7][8] In our previous study using a Japanese claims database, a preference change between levodopa monotherapy and combination therapy with DAs was observed between 2010 and 2017. 9 This change might be associated with the publication of the 2011 Japanese guidelines, which recommend DAs as the initial treatment in patients with PD.…”

Section: Introductionmentioning

confidence: 98%

“…Dopamine replacement therapy, used to ameliorate motor symptoms, remains the standard treatment for patients with PD since levodopa was introduced in the 1960s, 4,5 despite the development of new medications with various action mechanisms and effects. Recent Japanese research reported that levodopa is most commonly prescribed, followed by non‐ergot dopamine agonists (DAs), both as monotherapy and in combination with levodopa 6–8 . In our previous study using a Japanese claims database, a preference change between levodopa monotherapy and combination therapy with DAs was observed between 2010 and 2017 9 .…”

Section: Introductionmentioning

confidence: 99%

Non‐ergot dopamine agonist therapy for Parkinson's disease in Japan: A claims database analysis

Wada‐Isoe

Tsuboi

Kondo

et al. 2023

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

Background Levodopa monotherapy and combination therapy with non‐ergot dopamine agonists (DAs; pramipexole, ropinirole, and rotigotine) are commonly used in patients with Parkinson's disease (PD). Changes in prescription preferences for each DA were reported previously; however, information regarding the selection of individual DAs is insufficient. Aim To investigate the reasons for selecting each DA. Methods This observational study used a Japanese claims database (April 2008–July 2017). The percentage of patients prescribed each DA was analyzed by year (2010–2017). The change in DA prescriptions and prevalence of comorbidities before DA initiation or before replacement with another DA were analyzed from 2013. Results The database included 50,408 patients with PD who received ≥1 levodopa and/or DA prescriptions. Pramipexole was the most popular DA; however, its prescription has decreased since 2012. Ropinirole prescriptions remained relatively unchanged, while that of rotigotine tended to increase since its launch in 2013 and recently surpassed that of ropinirole. The most frequent pattern of change (both in addition and replacement) was from pramipexole to rotigotine. Differences were observed in the prevalence of comorbidities among DAs. Conclusion Pramipexole was often prescribed at the beginning of the study period; the decrease in its prescription frequency might be mainly related to new DA options. The frequent change from pramipexole to rotigotine might be associated with the different DA characteristics, which may be a factor influencing the choice of a specific DA.

show abstract

Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database

Cited by 14 publications

References 25 publications

Antiparkinsonian Medication Reconciliation as a Strategy to Improve Safety by Preventing Medication Errors

Antiparkinsonian Medication Reconciliation as a Strategy to Improve Safety by Preventing Medication Errors

Antiparkinsonian medication reconciliation: how preventing medication errors promotes therapeutic quality and safety

Non‐ergot dopamine agonist therapy for Parkinson's disease in Japan: A claims database analysis

Contact Info

Product

Resources

About